Immune Response: preclinical development program with new HIV vaccine candidate
Yahoo! FinanceThe Immune Response Corporation (Nasdaq: IMNR) announced today that it has initiated a preclinical development program with IR103, a new vaccine candidate for the prevention and treatment of HIV, the virus that causes AIDS. The program is based on the promising results obtained from proof-of-concept studies with IR103, and is designed to provide data that would support regulatory filings for Phase I clinical studies. IR103 combines AMPLIVAX(TM), an adjuvant being developed by Hybridon, Inc. (OTC Bulletin Board: HYBN) to enhance the immune response to a vaccine antigen, with the HIV-1 Immunogen technology employed in Remune(R), an immune-based therapeutic vaccine currently being evaluated in Phase II clinical trials by The Immune Response Corporation for the treatment of HIV infected individuals.
—Posted: November 3, 2003
More news headlines: This week | Last week | Search archive